(Q51378108)

4 April 2018

title

Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. (English)

1 reference

4 April 2018

main subject

type 2 diabetes

0 references

author

Signe Sørensen Torekov

1

1 reference

4 April 2018

Jens Juul Holst

4

1 reference

4 April 2018

author name string

M S Kipnes

2

1 reference

4 April 2018

R E Harley

3

1 reference

4 April 2018

M R Ehlers

5

1 reference

4 April 2018

publication date

1 July 2011

1 reference

4 April 2018

Diabetes, Obesity and Metabolism

published in

1 reference

4 April 2018

volume

13

1 reference

4 April 2018

issue

7

1 reference

4 April 2018

page(s)

639-643

1 reference

4 April 2018

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01388.X

10.1111/J.1463-1326.2011.01388.X

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

21362122

1 reference

4 April 2018